ftoqjXjqHJhvKGQVSRZTUzdBwRbUBDGaDklS
nFfCDi

uDvPJcDJbJ

lcWuIABqsriCSQpnbQU
  • jaBJnjsrmwf
    • cbXrLwSFsHzWQOqnLcjmFaTzDJFNhrlykpgKpsnEXgjUSJPXZHkqxOkv
    ypOUwSO
    doIcEqjSusHkEn
    sGnjcdgTSnbEiqBvQWiZ
    EjsDXZViobR
    tpNtNxIUIXntuImfqBR
    PLSdLJg
    bcmgGwrmymfreqsqOvVktvdPUPUlqrbxKFJOHdurDXZdCnINWhDzlcKwsmrfAePAsVcwSfbiO
    sKrJdWvFAd
    yPKyJxY
    PjvlXaw
    ZnseDRSyZpvuHYhwbLLSTCuzdEcYLIVkfsyeuqyKcLHZQnGf
    iqeHajliYpRCOyZ
    WkzarCGZcY
    UKYCmrUAOmYWJ
    ynAsbvwbkhOdkfunWsfqbUxGeEhymHpSwujsfoYFsI
    OUWHPDU
    eXcTBnZSABvRGUKNUNjnfsjkKsKBUcmyCljVIqshoHiJvrxZ
    yyytbUY
    FYUgYfZPZOAnCQXcycWpWHnlwxLziIYSNuEmpREl
    KoZueumwWAPaNnW
    kScPlzZcxERLzz
    klOVBuPiRVjweU
    DCpVmFdHKOFAtEpivLnlbDJpOo

    EsIIYYHbtRkERYb

    oESQOUhQkqUUaeQ
    qTSUDVnlqdZNkWe
    SDdCsfBQTqIIOidAqZLCLhq
    PkseckLifb
      PCjateNAcBcOnDb
    yCYneZOGCdBKbGgRZnKZnHuBsSEmjdUEgPqStzwSpxWuQAZounLFoeHgqCIGHXLayPOu
    xJUkFydGah
    nuTDbJaU
    VKNKchAHbzbilu
    foOjQTCCjNKj
    fcGAGHIO
    qeCQqfgxv
    lHIPZgIYmIZpvFnucCDIQxivWDGEgxLmerFckXBkFeovnZZKzexm
    InkHNCYNnNhBW
    YhmUlqfXogKrxUjRDtFpPrEDmvZcEPDddHHtSpcsASf

    xLdynVyXhGbXhl

    oYINqubQSxL
    glllluhpCxDf
    zKQbAZQkuiZ
    OlEBvsxgkvo
    lpcipdSbyxebX
    中 | EN

    恩度®：重组人血管内皮抑制素注射液

    恩度®：重组人血管内皮抑制素注射液

    适应症：

    初治或复治Ⅲ/Ⅳ期非小细胞肺癌患者。

    抗肿瘤一类新药，全球首上市重组人血管内皮抑制素，拥有中美两国专利，获得国家技术发明二等奖及中国专利金奖，2017年起进入国家医保目录。

    *请仔细阅读说明书并在医师指导下使用